Literature DB >> 24768363

Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms.

Adam J Doyle1, Eileen M Redmond1, David L Gillespie2, Peter A Knight1, John P Cullen1, Paul A Cahill3, David J Morrow4.   

Abstract

OBJECTIVE: The molecular mechanisms leading to the development of abdominal aortic aneurysms (AAAs) remain poorly understood. The aim of this study was to determine the expression of Sonic Hedgehog (SHh), transforming growth factor β (TGF-β), and Notch signaling components in human aneurysmal and nonaneurysmal aorta in vivo.
METHODS: Paired tissue samples were obtained from aneurysmal and nonaneurysmal (control) segments of the aortic wall of eight patients with suitable anatomy undergoing open repair of infrarenal AAAs. Protein and messenger RNA (mRNA) expression levels were determined by Western blot and quantitative real-time polymerase chain reaction analysis.
RESULTS: Aneurysm development resulted in a significant reduction in vascular smooth muscle (vSMC) differentiation genes α-actin and SMC22α at both mRNA and protein levels. In parallel experiments, an 80.0% ± 15% reduction in SHh protein expression was observed in aneurysmal tissue compared with control. SHh and Ptc-1 mRNA levels were also significantly decreased, by 82.0% ± 10% and 75.0% ± 5%, respectively, in aneurysmal tissue compared with nonaneurysmal control tissue. Similarly, there was a 50.0% ± 9% and 60.0% ± 4% reduction in Notch receptor 1 intracellular domain and Hrt-2 protein expression, respectively, in addition to significant reductions in Notch 1, Notch ligand Delta like 4, and Hrt-2 mRNA expression in aneurysmal tissue compared with nonaneurysmal tissue. There was no change in Hrt-1 expression observed in aneurysmal tissue compared with control. In parallel experiments, we found a 2.2 ± 0.2-fold and a 5.6 ± 2.2-fold increase in TGF-β mRNA and protein expression, respectively, in aneurysmal tissue compared with nonaneurysmal tissue. In vitro, Hedgehog signaling inhibition with cyclopamine in human aortic SMCs resulted in decreased Hedgehog/Notch signaling component and vSMC differentiation gene expression. Moreover, cyclopamine significantly increased TGF-β1 mRNA expression by 2.6 ± 0.9-fold.
CONCLUSIONS: These results suggest that SHh/Notch and TGF-β signaling are differentially regulated in aneurysmal tissue compared with nonaneurysmal tissue. Changes in these signaling pathways and the resulting changes in vSMC content may play a causative role in the development of AAAs.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24768363      PMCID: PMC4208950          DOI: 10.1016/j.jvs.2014.02.053

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  27 in total

1.  Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta.

Authors:  S Topouzis; M W Majesky
Journal:  Dev Biol       Date:  1996-09-15       Impact factor: 3.582

Review 2.  Patient-specific biomechanical profiling in abdominal aortic aneurysm development and rupture.

Authors:  Amir H Malkawi; Robert J Hinchliffe; Yun Xu; Peter J Holt; Ian M Loftus; Matt M Thompson
Journal:  J Vasc Surg       Date:  2010-04-14       Impact factor: 4.268

Review 3.  TGF-β signaling in aortic aneurysm: another round of controversy.

Authors:  Fuyu Lin; Xiao Yang
Journal:  J Genet Genomics       Date:  2010-09       Impact factor: 4.275

Review 4.  Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins.

Authors:  Eric C Lai
Journal:  EMBO Rep       Date:  2002-09       Impact factor: 8.807

5.  Notch 1 and 3 receptor signaling modulates vascular smooth muscle cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway.

Authors:  Catherine Sweeney; David Morrow; Yvonne A Birney; Seamus Coyle; Colm Hennessy; Agnieszka Scheller; Philip M Cummins; Dermot Walls; Eileen M Redmond; Paul A Cahill
Journal:  FASEB J       Date:  2004-07-09       Impact factor: 5.191

6.  Smooth muscle Notch1 mediates neointimal formation after vascular injury.

Authors:  Yuxin Li; Kyosuke Takeshita; Ping-Yen Liu; Minoru Satoh; Naotsugu Oyama; Yasushi Mukai; Michael T Chin; Luke Krebs; Michael I Kotlikoff; Freddy Radtke; Thomas Gridley; James K Liao
Journal:  Circulation       Date:  2009-05-11       Impact factor: 29.690

Review 7.  Notch signaling in development and disease.

Authors:  J A Harper; J S Yuan; J B Tan; I Visan; C J Guidos
Journal:  Clin Genet       Date:  2003-12       Impact factor: 4.438

Review 8.  Communicating with Hedgehogs.

Authors:  Joan E Hooper; Matthew P Scott
Journal:  Nat Rev Mol Cell Biol       Date:  2005-04       Impact factor: 94.444

9.  The Murine Angiotensin II-Induced Abdominal Aortic Aneurysm Model: Rupture Risk and Inflammatory Progression Patterns.

Authors:  Richard Y Cao; Tim Amand; Matthew D Ford; Ugo Piomelli; Colin D Funk
Journal:  Front Pharmacol       Date:  2010-07-14       Impact factor: 5.810

10.  Perivascular delivery of Notch 1 siRNA inhibits injury-induced arterial remodeling.

Authors:  Eileen M Redmond; Weimin Liu; Katie Hamm; Ekaterina Hatch; Paul A Cahill; David Morrow
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more
  17 in total

Review 1.  Aetiology and management of hereditary aortopathy.

Authors:  Aline Verstraeten; Ilse Luyckx; Bart Loeys
Journal:  Nat Rev Cardiol       Date:  2017-01-19       Impact factor: 32.419

2.  Mechanisms underlying the inhibitory effects of probucol on elastase-induced abdominal aortic aneurysm in mice.

Authors:  Cong Chen; Yunxia Wang; Yini Cao; Qinyu Wang; Gulinigaer Anwaier; Qingyi Zhang; Rong Qi
Journal:  Br J Pharmacol       Date:  2019-11-03       Impact factor: 8.739

Review 3.  Updates of Recent Aortic Aneurysm Research.

Authors:  Frank M Davis; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

Review 4.  Abdominal aortic aneurysm: novel mechanisms and therapies.

Authors:  Frank M Davis; Debra L Rateri; Alan Daugherty
Journal:  Curr Opin Cardiol       Date:  2015-11       Impact factor: 2.161

5.  Wnt16 attenuates TGFβ-induced chondrogenic transformation in vascular smooth muscle.

Authors:  Kelly E Beazley; Dmitry Nurminsky; Florence Lima; Chintan Gandhi; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-22       Impact factor: 8.311

6.  RUNX3 is up-regulated in abdominal aortic aneurysm and regulates the function of vascular smooth muscle cells by regulating TGF-β1.

Authors:  Zhongxiao Zhou; Haimeng Zhou; Xin Zou; Xiaowei Wang
Journal:  J Mol Histol       Date:  2021-11-23       Impact factor: 3.156

7.  TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.

Authors:  Stoyan N Angelov; Jie Hong Hu; Hao Wei; Nathan Airhart; Minghui Shi; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

8.  GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.

Authors:  Jianlong Li; Jinquan Cai; Shihong Zhao; Kun Yao; Ying Sun; Yongli Li; Lingchao Chen; Ruiyan Li; Xiuwei Zhai; Junhe Zhang; Chuanlu Jiang
Journal:  J Exp Clin Cancer Res       Date:  2016-11-28

Review 9.  Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition.

Authors:  Shu-Jin He; Chu-Qi Xiang; Yu Zhang; Xiang-Tong Lu; Hou-Wen Chen; Li-Xia Xiong
Journal:  Onco Targets Ther       Date:  2017-07-12       Impact factor: 4.147

10.  Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.

Authors:  Albert Busch; Martin Busch; Claus-Jürgen Scholz; Richard Kellersmann; Christoph Otto; Ekaterina Chernogubova; Lars Maegdefessel; Alma Zernecke; Udo Lorenz
Journal:  Int J Mol Sci       Date:  2016-01-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.